ASXCLEO Commences Analytical Validation Ahead of FDA Submission
other announcement
COV
Pharmaceuticals, Biotechnology & Life Sciences
Cleo Diagnostics
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 24 Aug 2026
- Reported shorts
- 6.3K
- Shares on issue
- 137.112M
Cleo Diagnostics (COV) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Cleo Files Patents for its Ovarian Cancer Screening Test
other announcement
CLEO Commences Ovarian Cancer Screening Test Development
other announcement
Notice of Annual General Meeting/Proxy Form
other announcement
Google NewsCLEO Diagnostics (ASX:COV) Gains Ground - What Investors Should Watch Next? - Kalkine
CLEO Diagnostics (ASX:COV) Gains Ground - What Investors Should Watch Next? Kalkine
Small CapsCleo Diagnostics Selects Bio-Techne’s US Laboratory for Pivotal Ovarian Cancer Test Validation
Cleo Diagnostics taps Bio-Techne's US lab for pivotal validation of its pre-surgical ovarian cancer test ahead of a 510(k) FDA filing in H1 2027.
Notice Required Under ASX Listing Rule 3.13.1
other announcement
CLIA Certified Lab selected - Pivotal US Clinical Validation
other announcement
Is Cleo Diagnostics (ASX:COV) In A Good Position To Invest In Growth? - simplywall.st
Is Cleo Diagnostics (ASX:COV) In A Good Position To Invest In Growth? simplywall.st
CLEO Receives First Batch of Commercial Test Kits
other announcement
Change of Director's Interest Notice x 4
director_dealing announcement
Cleo Diagnostics (ASX:COV) Shares Fall: Is the Pullback Putting the Cancer-Diagnostics Stock on the Watchlist? - Kalkine
Cleo Diagnostics (ASX:COV) Shares Fall: Is the Pullback Putting the Cancer-Diagnostics Stock on the Watchlist? Kalkine
CLEO Diagnostics (ASX:COV) Slips as ASX Biotech Volatility Stays in Focus - Kalkine
CLEO Diagnostics (ASX:COV) Slips as ASX Biotech Volatility Stays in Focus Kalkine
Why Has Cleo Diagnostics (ASX:COV) Gained Nearly 27% Over the Past Year? - Kalkine
Why Has Cleo Diagnostics (ASX:COV) Gained Nearly 27% Over the Past Year? Kalkine
CLEO Diagnostics (ASX:COV) Is Under Pressure. Here’s a Possible Explanation - Kalkine
CLEO Diagnostics (ASX:COV) Is Under Pressure. Here’s a Possible Explanation Kalkine
CLEO Commences Kit Manufacturing Ahead of FDA Submission
other announcement
Sample Collection Completion for Pivotal US Clinical Trial
other announcement
CLEO Optimises Biomarker Panel Ahead of FDA Submission
other announcement
CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
other announcement
Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
other announcement
CLEO Appoints First Key Opinion Leader to Support US Market
other announcement
COV Commences Health Economic Study-Support US Market Entry
other announcement